Researchers have made what the International Aids Society called an “exciting breakthrough” in the fight against HIV/AIDS. Pharmaceutical company Sanofi and the United States National Institutes of Health (NIH) together engineered an antibody that can tackle 99 percent of HIV strains. The antibody has prevented infection in primates.


Sanofi, National Institutes of Health, HIV, HIV/AIDS, AIDS, health, antibody, tri-specific antibody, research

The new antibody can interact with three crucial parts of the HIV virus. And it targets more strains than naturally occurring antibodies, the best of which attack 90 percent of strains. Researchers ran experiments on 24 monkeys. They gave one antibody to eight monkeys, a different one to another eight, and the final eight they gave the new antibody. Five days later they exposed the monkeys to strains of SHIV, a monkey form of HIV. None of those given the new antibody developed an infection.

Related: 44-year-old British man could be the first to receive HIV cure

Sanofi, National Institutes of Health, HIV, HIV/AIDS, AIDS, health, antibody, tri-specific antibody, research

The antibody is called a tri-specific antibody because it’s a combination of three broadly neutralizing antibodies. NIH described it as a three-in-one antibody. Broadly neutralizing antibodies tackle “something fundamental to HIV” according to the BBC. Sanofi Chief Scientific Officer Gary Nabel said tri-specific antibodies “can block multiple targets with a single agent.” He told the BBC, “They are more potent and have greater breadth than any single naturally occurring antibody that’s been discovered.”

International Aids Society president Linda-Gail Bekker told the BBC, “These super-engineered antibodies seem to go beyond the natural and could have more applications than we have imagined to date. It’s early days yet, and as a scientist I look forward to seeing the first trials get off the ground in 2018. As a doctor in Africa, I feel the urgency to confirm these findings in humans as soon as possible.”

The journal Science published the study last week. Scientists from Harvard Medical School, Massachusetts Institute of Technology, and The Scripps Research Institute also collaborated on the research. Human trials are slated to begin next year.

Via the BBC and the National Institutes of Health

Images via NIAID on Flickr and Sanofi